Adaptimmune Therapeutics

2024 highlights include UChicago Medicine's research milestones, Ascentage Pharma's presentations on cancer therapies, breakthroughs in cancer detection and treatment, and advancements in plant proteins for cardiovascular health. Innovations in AI and healthcare analytics also mark significant progress in oncology and patient care.

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.

The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.

The ASGCT's Q3 2024 Gene, Cell, & RNA Therapy Landscape Report highlights the approval of Adaptimmune Therapeutics’ Tecelra for synovial sarcoma and a shift towards nononcology targets. The report tracks clinical trials, therapeutic modalities, and financing trends, showing a stable increase in new programs and a robust pipeline moving through phases 1-3.

The global cancer gene therapy market is projected to grow from $2.3B in 2023 to $8.8B by 2030, driven by advances in gene editing, personalized medicine, and rising cancer incidence. Key technologies like CRISPR and next-generation sequencing are shaping the market, while challenges include high costs and regulatory hurdles.

Syros Pharmaceuticals' phase III study for tamibarotene in MDS missed primary endpoint; Amgen's stock steady despite analyst report; Adaptimmune reports positive results for lete-cel; Daiichi Sankyo and Astrazeneca submit new BLA for lung cancer treatment; Apollo Therapeutics signs $938 million deal with Sunshine Lake Pharma; study identifies quiescent cancer stem cells in glioblastoma relapse; Modifi Biosciences acquired by Merck for up to $1.3 billion.

The hemoglobinopathies treatment market is projected to grow from $8.2 billion in 2023 to $13.2 billion by 2028, driven by genetic inheritance, advancements in cell-based gene therapies, and personalized medicine. Key players include Pfizer, Sanofi, and Vertex Pharmaceuticals.

FDA approves Tecelra®, a TCR therapy for unresectable or metastatic synovial sarcoma, offering hope for solid tumor treatment. Unlike CAR-T, Tecelra targets intracellular MAGE-A4 antigens, expanding target options. Clinical trials showed 43% response rate, with 17% lasting ≥12 months. Challenges include complex manufacturing and side effects like cytokine release syndrome. Future research aims to expand TCR-T therapy to other solid tumors and new antigens.

Vironexis Biotherapeutics' VNX-101, an AAV vector-based gene therapy, received FDA clearance for a phase 1/2 trial in CD19+ acute lymphoblastic leukemia. CARsgen completed patient enrollment in a pivotal phase 2 trial for satricabtagene autoleucel in China for advanced gastric/gastroesophageal cancer. Adaptimmune's TCR T-cell therapy afami-cel received FDA approval for synovial sarcoma. Mustang Bio's MB-106 CAR-T therapy achieved a 90% response rate in Waldenstrom macroglobulinemia patients. Wugen's WU-CART-007 showed improved overall response rates with an enhanced lymphodepletion regimen in T-cell malignancy patients.